Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
| ▸ | CTSC | P53634 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16904987 | 1.00 | CYP1A2 (0.31) | CYP1A2CYP2D6ALOX15CYP2C19SLC1A3 | |
| SCHEMBL21896074 | 0.85 | CYP2D6 (0.47) | CYP1A2CYP2D6ALOX15CYP2C19SLC1A3 | |
| SCHEMBL3450012 | 0.85 | CYP2D6 (0.47) | CYP1A2CYP2D6ALOX15CYP2C19SLC1A3 | |
| SCHEMBL9297990 | 0.85 | CYP2D6 (0.47) | CYP1A2CYP2D6ALOX15CYP2C19SLC1A3 | |
| SCHEMBL3450013 | 0.85 | CYP2D6 (0.47) | CYP1A2CYP2D6ALOX15CYP2C19SLC1A3 | |
| SCHEMBL3771173 | 0.85 | CYP2D6 (0.47) | CYP1A2CYP2D6ALOX15CYP2C19SLC1A3 | |
| SCHEMBL7340980 | 0.85 | CYP2D6 (0.47) | CYP1A2CYP2D6ALOX15CYP2C19SLC1A3 | |
| Hydrochloric Acid SCHEMBL16287994 | 0.84 | CYP1A2 (0.46) | CYP1A2CYP2D6ALOX15CYP2C19SLC1A3 | |
| Hydrochloric Acid SCHEMBL16288453 | 0.84 | CYP1A2 (0.46) | CYP1A2CYP2D6ALOX15CYP2C19SLC1A3 | |
| Hydrochloric Acid SCHEMBL17600576 | 0.84 | CYP1A2 (0.46) | CYP1A2CYP2D6ALOX15CYP2C19SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135270-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | BRISTOL-MYERS SQUIBB COMPANY | 2014-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135270-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | BAX, API5, BCL2 | CYP1A2 4761/4885CYP2D6 4717/4885ALOX15 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.